Down-regulation of erythroblast Fas/FasL in pregnant mice
. | Fas-positive cells, % . | . | . | FasL-positive cells, % . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | Control*; n = 5 . | Pregnancy; n = 5 . | P† . | Control*; n = 5 . | Pregnancy; n = 5 . | P† . | ||||
| Spleen | ||||||||||
| ProE | 35 ± 8 | 16 ± 5 | — | 55 ± 6 | 40 ± 4 | — | ||||
| Ery.A | 36 ± 3 | 25 ± 3 | .022 | 73 ± 5 | 59 ± 3 | .042 | ||||
| Ery.B | 4 ± 1 | 1.5 ± 0.2 | — | 17 ± 5 | 9 ± 2 | — | ||||
| Ery.C | 0.6 ± 0.2 | 0.4 ± 0.1 | — | 2 ± 1.5 | 0.8 ± 0.4 | — | ||||
| Non-Ery | 30 ± 4 | 33 ± 5 | — | 5 ± 0.6 | 5 ± 1 | — | ||||
| Bone marrow | ||||||||||
| ProE | 18 ± 4 | 12 ± 4 | — | 43 ± 10 | 16 ± 4 | — | ||||
| Ery.A | 13 ± 1 | 9 ± 1 | .044 | 59 ± 8 | 28 ± 3 | .013 | ||||
| Ery.B | 0.7 ± 0.1 | 0.7 ± 0.1 | — | 7 ± 2 | 4 ± 2 | — | ||||
| Ery.C | 0.3 ± 0.1 | 0.4 ± 0.1 | — | 1 ± 0.5 | 0.6 ± 0.4 | — | ||||
| Non-Ery | 20 ± 2 | 24 ± 5 | — | 9 ± 2 | 12 ± 1 | — | ||||
. | Fas-positive cells, % . | . | . | FasL-positive cells, % . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | Control*; n = 5 . | Pregnancy; n = 5 . | P† . | Control*; n = 5 . | Pregnancy; n = 5 . | P† . | ||||
| Spleen | ||||||||||
| ProE | 35 ± 8 | 16 ± 5 | — | 55 ± 6 | 40 ± 4 | — | ||||
| Ery.A | 36 ± 3 | 25 ± 3 | .022 | 73 ± 5 | 59 ± 3 | .042 | ||||
| Ery.B | 4 ± 1 | 1.5 ± 0.2 | — | 17 ± 5 | 9 ± 2 | — | ||||
| Ery.C | 0.6 ± 0.2 | 0.4 ± 0.1 | — | 2 ± 1.5 | 0.8 ± 0.4 | — | ||||
| Non-Ery | 30 ± 4 | 33 ± 5 | — | 5 ± 0.6 | 5 ± 1 | — | ||||
| Bone marrow | ||||||||||
| ProE | 18 ± 4 | 12 ± 4 | — | 43 ± 10 | 16 ± 4 | — | ||||
| Ery.A | 13 ± 1 | 9 ± 1 | .044 | 59 ± 8 | 28 ± 3 | .013 | ||||
| Ery.B | 0.7 ± 0.1 | 0.7 ± 0.1 | — | 7 ± 2 | 4 ± 2 | — | ||||
| Ery.C | 0.3 ± 0.1 | 0.4 ± 0.1 | — | 1 ± 0.5 | 0.6 ± 0.4 | — | ||||
| Non-Ery | 20 ± 2 | 24 ± 5 | — | 9 ± 2 | 12 ± 1 | — | ||||